Pureos Bioventures
VC Fund
Küsnacht, Switzerland
Pureos Bioventures is a new venture capital fund located in Zurich to exclusively invest in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug formats
- Total investments:
- 35
- Last investment:
- Lead investor:
- 37%
- Fund size:
- $205M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Pureos Bioventures invests in
Stages Pureos Bioventures invests in
Countries Pureos Bioventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Series A
- $15M–$123M
- Series B
- $6.6M–$100M
- Series C
- $22M–$125M
Investment Focus
Industry
- Biotechnology 19 (54%)
- Therapeutics 11 (31%)
- Medical 9 (26%)
- Health Care 9 (26%)
- Biopharma 4 (11%)
Stage
- Series A 11 (31%)
- Series B 6 (17%)
- Series C 6 (17%)
- Seed 5 (14%)
- Series F 1 (3%)
Country
- France 5 (14%)
- Switzerland 5 (14%)
- United States 4 (11%)
- The Netherlands 4 (11%)
- Sweden 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Klaus Breiner
Managing Partner & Founding partner
|
Managing Partner & Founding partner | Total investments: 5 | Find email | |
Martin Münchbach
Managing Partner & Founding Partner
|
Managing Partner & Founding Partner | Total investments: 12 | Find email | |
Dominik Escher
Managing Partner & Founding partner
|
Managing Partner & Founding partner | Total investments: 6 | Find email | |
Ximing Ding
Investment Manager
|
Investment Manager | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tavo Biotherapeutics
|
Tavo Biotherapeutics is a biotech company that develops injection therapies for eye diseases. | $17M / Series A / Jun 02, 2026 | |
Adcytherix
|
Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $122.8M / Series A / Oct 16, 2025 | |
Callio Therapeutics
|
Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits. | $187M / Series A / Mar 03, 2025 | |
AnaCardio
|
AnaCardio is a clinical stage biopharmaceutical company developing novel drugs to treat heart failure. | $18.4M / Series A / Jan 09, 2025 | |
Citryll
|
Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands. | $89.7M / Series B / Dec 09, 2024 | |
Alentis Therapeutics
|
Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases. | $181.4M / Series D / Nov 12, 2024 | |
Vico Therapeutics
|
Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarilyaffecting girls that enable clients with providing therapy for it.Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands. | $12.3M / Series B / Jun 24, 2024 | |
|
Adcytherix
|
Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC) to treat diseases with a high unmet need, including cancer. | $32.2M / Seed / Jun 11, 2024 | |
Memo Therapeutics
|
Memo Therapeutics AG (MEMO) is an innovator in the field of antibody discovery and immune repertoire analysis.Its MemoMAB™ platform creates a recombinant in vitro copy of an individual’s B cell / antibody repertoire, which is then banked as a library. The resulting unique, large and relevant antibody libraries represent the individual’simmune repertoire and are expected to contain an unprecedented number of relevant and rare antibodies. This leads to entirely new possibilities in immune repertoire analysis and antibody discovery.MemoMAB™ is deployed in proprietary antibody lead discovery programs and is made available in collaborations. | $22M / Series C / May 07, 2024 | |
PulseSight Therapeutics
|
PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness. | Seed / Feb 28, 2024 | |
| See all 35 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Pureos Bioventures invest in?
Pureos Bioventures invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series A and Series B stage. Most of the 35 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Pureos Bioventures's check size?
Pureos Bioventures typically joins rounds of $15M–$123M at Series A, $6.6M–$100M at Series B and $22M–$125M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Pureos Bioventures participates in.
How do I contact Pureos Bioventures?
Public channels for Pureos Bioventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pureos Bioventures?
The team at Pureos Bioventures includes Klaus Breiner (Managing Partner & Founding partner), Martin Münchbach (Managing Partner & Founding Partner) and Dominik Escher (Managing Partner & Founding partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
